INKT Earnings Date: Nov 12, 2026 (Estimated) — MiNK Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is INKT's next earnings date?
MiNK Therapeutics, Inc. (INKT) is expected to report earnings on Thursday, November 12, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.50 on revenue of $875,000.
How did INKT do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), MiNK Therapeutics, Inc. posted EPS of -$0.62 versus the -$0.60 estimate, a miss of 3.3%. Revenue was $0. The stock's 1-day post-earnings move was -3.2%.
How much does INKT stock move after earnings?
INKT beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.0% (up or down) in the day after earnings.
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.60 | -0.62 | -3.33% | $0 | ❌ Miss | -3.17% | -2.02% | +5.63% |
| 2026-05-15 | Q1 2026 | -0.77 | -0.57 | +25.97% | $0 | ✅ Beat | +2.00% | +4.09% | +19.27% |
| 2026-03-31 | Q4 2025 | -0.68 | -0.56 | +17.65% | $0 | ✅ Beat | +0.10% | +10.27% | +12.26% |
| 2025-11-14 | Q3 2025 | -0.86 | -0.65 | +24.42% | $0 | ✅ Beat | -3.56% | -17.70% | -7.87% |
| 2025-08-14 | Q2 2025 | -0.55 | -1.06 | -92.73% | $0 | ❌ Miss | -12.46% | -17.31% | -17.71% |
| 2025-03-18 | Q4 2024 | -0.50 | -0.62 | -24.00% | $0 | ❌ Miss | -3.29% | +0.59% | -9.04% |
| 2024-11-14 | Q3 2024 | -0.08 | -0.05 | +37.50% | $0 | ✅ Beat | -5.59% | -11.27% | -22.46% |
| 2024-08-13 | Q2 2024 | -0.10 | -0.07 | +30.00% | $0 | ✅ Beat | +1.63% | +0.48% | -7.19% |
Showing last 8 quarters.